Current treatments for Alzheimer's disease often face limitations, including adverse effects such as ARIA (Amyloid-Related Imaging Abnormalities), and may not effectively address the underlying neuroinflammation contributing to disease progression. Degenerative brain and autoimmune diseases require novel therapeutic approaches that can modulate the immune environment in the brain without causing harmful side effects.

Illimis Therapeutics is developing innovative therapies for degenerative brain and autoimmune diseases by targeting TAM (Tyro3, Axl, Mer) receptors to reduce neuroinflammation and improve the immune environment within the central nervous system. Their GAIA-Aβ platform aims to enhance the quality of life for Alzheimer's patients by overcoming the limitations of existing amyloid-targeting therapies, particularly the adverse effects associated with ARIA. This approach focuses on modulating the immune response in the brain to promote clearance of amyloid plaques without triggering excessive inflammation or other detrimental effects. By selectively targeting TAM receptors, Illimis seeks to restore immune homeostasis and promote neuroprotection, potentially slowing or reversing the progression of Alzheimer's disease and other neurodegenerative conditions.

Targets TAM receptors to modulate neuroinflammation and improve the brain's immune environment.

GAIA-Aβ platform designed to address the limitations of existing Alzheimer's treatments, specifically ARIA.

Focuses on promoting amyloid plaque clearance without triggering excessive inflammation.

Aims to restore immune homeostasis and promote neuroprotection in the central nervous system.

Developing therapies for both degenerative brain and autoimmune diseases.

The primary target audience includes individuals suffering from Alzheimer's disease and other neurodegenerative conditions, as well as their families and caregivers, and pharmaceutical companies seeking novel therapeutic approaches for these diseases.